1-(6-氯哒嗪-3-基)-4-羟基哌啶 | 89937-26-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(6-氯哒嗪-3-基)-4-羟基哌啶
• 中文别名: 1-(6-氯-3-哒嗪基)-4-羟基哌啶
• 英文名称: 1-(6-chloro-pyridazin-3-yl)-piperidin-4-ol
• 英文别名: 1-(6-chloropyridazin-3-yl)piperidin-4-ol
• CAS: 89937-26-8
• 化学式: C₉H₁₂ClN₃O
• mdl: MFCD05864736
• 分子量: 213.667
• InChiKey: GYVIZUPSUNWREG-UHFFFAOYSA-N

物化性质

• 沸点：
  453.3±45.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  49.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933990090
• WGK Germany：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(6-Chloropyridazin-3-yl)piperidin-4-ol
Synonyms: 1-(6-Chloropyridazin-3-yl)-4-hydroxypiperidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(6-Chloropyridazin-3-yl)piperidin-4-ol
CAS number: 89937-26-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H12ClN3O
Molecular weight: 213.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(6-氯哒嗪-3-基)-4-羟基哌啶 在 [1,1'-bis(diphenylphosphino)ferrocene]PdCl₂(II)*CH₂Cl₂ 偶氮二甲酸二叔丁酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 25.0~100.0 ℃ 、1.38 MPa 条件下， 反应 5.0h， 生成 methyl 6-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]pyridazine-3-carboxylate
  参考文献：
  名称：

  Discovery of Potent, Selective, Orally Bioavailable Stearoyl-CoA Desaturase 1 Inhibitors

  摘要：

  Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin deficiency-induced and diet-induced obesity, with greater whole body insulin sensitivity than wild-type animals. In this work, we have discovered a series of potent, selective, orally bioavailable SCD1 inhibitors based on a known pyridazine carboxamide template. The representative lead inhibitor 28c also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

  DOI：

  10.1021/jm070219p
• 作为产物：
  描述：

  4-羟基哌啶 、 3,6-二氯哒嗪 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 以89%的产率得到1-(6-氯哒嗪-3-基)-4-羟基哌啶
  参考文献：
  名称：

  [EN] GLUTAMINASE INHIBITORS
  [FR] INHIBITEURS DE GLUTAMINASE

  摘要：

  一种化合物，或其药学上可接受的盐，其结构如下：公式A，其中A是一个环；Y1和Y2分别独立地是N或C，具有适当的价；X1和X2分别独立地是-NH-、-O-、-CH2-O-、-NH-CH2-或-N(CH3)-CH2-，但是当X1和X2中至少有一个是-CH2-O-、-NH-CH2-或-N(CH3)-CH2-时，那么-CH2-直接连接到A；a和b分别独立地是0或1；c和d分别独立地是0或1；Z1和Z2分别独立地是一个杂环；R1和R2分别独立地是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、氨基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基；但是如果Y1和Y2分别是C，则a为1且b为1；如果Y1和Y2分别是N，则a为0且b为0；如果Y1是N且Y2是C，则a=0且b=1；如果Y1是C且Y2是N，则a=1且b=0；如果c=0且d=0，则R1和R2都是氨基；如果c为1且d为1，则R1和R2都不是氨基；如果c为0且d为1，则R1是氨基且R2是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基；如果c为1且d为0，则R2是氨基且R1是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基。

  公开号：

  WO2016054388A1

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Sheppard S. George

  公开号：US20070203143A1

  公开（公告）日：2007-08-30

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  抑制蛋白激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法被披露。
• [EN] GLUTAMINASE INHIBITORS<br/>[FR] INHIBITEURS DE GLUTAMINASE
  申请人：UNIV PITTSBURGH

  公开号：WO2016054388A1

  公开（公告）日：2016-04-07

  A compound, or a pharmaceutically acceptable salt thereof, having a structure of: Formula A wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently -NH-, -0-, -CH2-0-, -NH-CH2-, or -N(CH3)-CH2-, provided that when at least one of X1 and X2 is -CH2-0-, -NH-CH2-, or -N(CH3)-CH2- then the - CH2- is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and Y2 is C, then a=0 and b=l; provided that if Y1 is C and Y2 is N, then a=l and b=0; provided that if c=0 and d=0, then R1 and R2 are both amino; provided that if c is 1 and d is 1, then both R1 and R2 are not amino; provided that if c is 0 and d is 1, then R1 is amino and R2 is optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; and provided that if c is 1 and d is 0, then R2 is amino and R1 is optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

  一种化合物，或其药学上可接受的盐，其结构如下：公式A，其中A是一个环；Y1和Y2分别独立地是N或C，具有适当的价；X1和X2分别独立地是-NH-、-O-、-CH2-O-、-NH-CH2-或-N(CH3)-CH2-，但是当X1和X2中至少有一个是-CH2-O-、-NH-CH2-或-N(CH3)-CH2-时，那么-CH2-直接连接到A；a和b分别独立地是0或1；c和d分别独立地是0或1；Z1和Z2分别独立地是一个杂环；R1和R2分别独立地是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、氨基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基；但是如果Y1和Y2分别是C，则a为1且b为1；如果Y1和Y2分别是N，则a为0且b为0；如果Y1是N且Y2是C，则a=0且b=1；如果Y1是C且Y2是N，则a=1且b=0；如果c=0且d=0，则R1和R2都是氨基；如果c为1且d为1，则R1和R2都不是氨基；如果c为0且d为1，则R1是氨基且R2是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基；如果c为1且d为0，则R2是氨基且R1是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基。
• AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Oballa Renata M.

  公开号：US20100004245A1

  公开（公告）日：2010-01-07

  Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式（I）的Azacycloalkane衍生物是选择性抑制stearoyl-coenzyme A delta-9去饱和酶（SCD1）相对于其他已知的stearoyl-coenzyme A去饱和酶的化合物。本发明的化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗和肝脂肪变性。
• Deoxytrifluoromethylation of Alcohols
  作者：Nicholas E. Intermaggio、Agustin Millet、Dali L. Davis、David W. C. MacMillan

  DOI：10.1021/jacs.2c04807

  日期：2022.7.13

  Deoxy-functionalization of alcohols represents a class of reactions that has had a profound impact on modern medicine. In particular, deoxyfluorination is commonly employed as a means to incorporate high-value fluorine atoms into drug-like molecules. Recently, the trifluoromethyl (CF3) group has garnered attention from medicinal chemists due to its ability to markedly improve the pharmaceutical properties

  醇的脱氧功能化代表了一类对现代医学产生深远影响的反应。特别是，脱氧氟化作用通常用作将高价值氟原子掺入类药物分子中的一种手段。最近，三氟甲基 (CF 3 ) 基团因其能够显着改善小分子候选药物的药物特性而受到药物化学家的关注。然而，迄今为止，仍然没有实现类似的醇脱氧三氟甲基化的通用方法。我们在此报告了铜金属光氧化还原介导的直接脱氧三氟甲基化，其中醇底物被苯并恶唑盐原位激活，用于 C(sp 3 )–CF 3债券形成。
• Expedient Access to Underexplored Chemical Space: Deoxygenative C(sp³)–C(sp³) Cross-Coupling
  作者：William L. Lyon、David W. C. MacMillan

  DOI：10.1021/jacs.3c01488

  日期：——

  bond-forming cross-couplings remains underexplored. Herein we report an N-heterocyclic carbene (NHC)-mediated deoxygenative alkylation of alcohols and alkyl bromides via nickel–metallaphotoredox catalysis. This C(sp3)–C(sp3) cross-coupling exhibits a broad scope and is capable of forming bonds between two secondary carbon centers, a longstanding challenge in the field. Highly strained three-dimensional

  醇是商业上丰富且结构多样的 sp 3杂化化学空间的储存库。然而，醇在 C-C 键形成交叉偶联中的直接利用仍未得到充分探索。在此，我们报道了通过镍-金属光氧化还原催化的N-杂环卡宾（NHC）介导的醇和烷基溴的脱氧烷基化。这种C(sp 3 )–C(sp 3 )交叉偶联表现出广泛的范围，并且能够在两个二级碳中心之间形成键，这是该领域长期存在的挑战。高应变的三维系统，如螺环、自行车和稠合环，是极好的底物，能够合成新的分子框架。药效团饱和环系统之间的连接很容易形成，代表了传统联芳基形成的三维替代方案。这种交叉偶联技术的实用性通过生物活性分子的加速合成而得到凸显。